Previous 10 | Next 10 |
InspireMD (NSPR) -19%.Reviva Pharmaceuticals (RVPH) -17%.RealNetworks RNWK -16% on preliminary estimates for its first-quarter, stock offering.Mechanical Technology (MKTY) -10% after subsidiary announces newest addition of the PBS-4100+ portable vibration and balancing system.S...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Sol-Gel Technologies (SLGL): FY net loss of $29.3M.Revenue of $8.8M (-61.6% Y/Y) beats by $0.5M.Press Release For further details see: Sol-Gel Technologies reports FY 2020 results
• Epsolay ® and Twyneo ® PDUFA goal date s set for April 26 , 2021 and August 1 , 2021 respectively • Top-line generic product revenue of $8. 7 million in fiscal 2020 ...
NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases...
NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases...
Sol-Gel Technologies's ([[SLGL]] +0.4%) marketing application seeking approval for Twyneo (benzoyl peroxide and tretinoin), for the treatment of acne vulgaris, has been accepted the the FDA. Action date is set at August 1, 2021.Twyneo is a proprietary fixed-dose combination of ...
- PDUFA Goal Date Set for August 1, 2021 - Potential to be the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin NESS ZIONA, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatolog...
Patented technology for slow release of topical formulations. Potentially the first single-active benzoyl peroxide to be approved as a prescription drug. Two late stage candidates. Funded sufficiently to pull through the anticipated approvals. For further details see: ...
Sol-Gel Technologies (SLGL): Q3 GAAP EPS of -$0.37 beats by $0.09.Revenue of $2.12M (-55.2% Y/Y) beats by $0.3M.Press Release For further details see: Sol-Gel Technologies EPS beats by $0.09, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...